Shmaila Saleem-Talib

Shmaila Saleem-Talib

Auto-generated profile, based on publicly available information

Shmaila Saleem-Talib

Department of Cardiology, Haga Teaching Hospital , The Hague

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 March 2025 in European Heart Journal
Verified
Journal Article
Open access
SSShmaila Saleem-Talib
Shmaila Saleem-Talib
CHCrispijn P R Hoevenaars
Crispijn P R Hoevenaars
NMNadine Molitor
Nadine Molitor
VDVincent J van Driel
Vincent J van Driel
JHJeroen van der Heijden
Jeroen van der Heijden
HRHemanth Ramanna
Hemanth Ramanna
Over the past decade, leadless pacing has undergone a rapid evolution, resulting in multiple leadless pacemaker (LPM) devices that offer advancements such as atrioventricular synchronized pacing in VDD mode, atrial stimulation, dual-chamber pacing, and longer battery longevity. Studies comparing LPMs with transvenous pacemakers (TVPMs) show a lower rate of device-related complications with LPMs. In the near future, LPMs could be combined with other devices such as non-transvenous implantable cardioverter-defibrillators to provide anti-tachycardia pacing or bradycardia pacing. Future prospectives for leadless cardiac resynchronization therapy and leadless conduction system pacing are being investigated. As LPMs continue to improve, their applications are anticipated to expand further improving patient outcome, promising a bright future for leadless pacing. In this review, the past, present, and future of leadless pacing are discussed with a focus on cutting-edge implantation techniques, clinical outcomes, and modern advancements of LPMs.

17 January 2019 in Pacing and Clinical Electrophysiology
Verified
Journal Article
Open access
PDF file
SSShmaila Saleem‐Talib
Shmaila Saleem‐Talib
VDVincent J. van Driel
Vincent J. van Driel
SCSevasti‐Maria Chaldoupi
Sevasti‐Maria Chaldoupi
TNTanja Nikolic
Tanja Nikolic
HWHarry van Wessel
Harry van Wessel
HRHemanth Ramanna
Hemanth Ramanna
Background Leadless pacing is generally performed from a femoral approach. However, the femoral route is not always available. Until now, data regarding implantation using a jugular approach other than a single case report is lacking. Methods Case records of all patients who underwent internal jugular venous (IJV) leadless pacemaker implantation (Micra, Medtronic) at our center were analysed retrospectively. Results 19 patients underwent IJV leadless pacemaker implantation, 9 female, mean age 77.5 ±9.6 yrs; permanent AF in all patients with normal left ventricular ejection fraction. Implant indication was AV conduction disturbance in 10, pre AV node ablation in 7 and replacement of a conventional VVI pacemaker in 2 (infection in 1 and lead malfunction in the other). The device was positioned at the superior septum in 7 patients, apicoseptal in 7 patients and midseptal in 5 patients. In 12 patients, a sufficient device position was obtained at the first attempt, in 3 at the 2nd, in 1 at the 3rd, in 1 at the 4th and in 2 at 6th attempt. The mean pacing threshold was 0.56± 0.39V at 0.24 ms pulse width, sensed amplitude was 9.1±3.2 mV , mean fluoroscopy duration 3.1±1.6 min. There were no vascular or other complications. At follow‐up electrical parameters remained stable in 18 of 19 patients. Conclusion Although experience is minimal, we suggest that the IJV approach is safe and may be considered in patients where the femoral approach is contraindicated. This article is protected by copyright. All rights reserved

25 July 2024 in EP Europace
Verified
Journal Article
Open access
PDF file
NMNadine Molitor
Nadine Molitor
SSShmaila Saleem-Talib
Shmaila Saleem-Talib
HRHemanth Ramanna
Hemanth Ramanna
DHDaniel Hofer
Daniel Hofer
ABAlexander Breitenstein
Alexander Breitenstein
JSJan Steffel
Jan Steffel
Leadless pacemaker therapy was introduced to overcome lead- and pocket-related complications in conventional transvenous pacemaker therapy. Implantation via the femoral vein, however, may not always be feasible. The aim of this study was to evaluate leadless pacemaker implantation using a jugular vein approach and compare it to the standard implantation approach through the femoral vein. The records of the first consecutive 100 patients undergoing MicraTM leadless pacemaker implantation via the right internal jugular vein from two centers were included in this study. Periprocedural safety and efficacy of the jugular approach were compared to the first 100 patients having undergone a femoral implantation approach at the University Hospital Zurich. 100 patients underwent successful implantation of a leadless pacemaker via the internal jugular vein (mean age, 81.18 ± 8.29, 60% males). Mean procedure time was 35.63 ± 10.29 min with a mean fluoroscopy time of 4.66 ± 5.16 min. The device was positioned at the inferior septum in 25 patients, at the high septum in 24 and mid-septum in 51 patients. The mean pacing threshold was 0.56 ± 0.35 V at 0.24 ms pulse width with a sensed amplitude of 10.0 ± 4.4 mV. At follow-up, electrical parameters remained stable in all patients. Compared with femoral implantation, patients undergoing jugular transvenous pacemaker implantation were of similar age and had similar comorbidities. Mean procedure- (48.9 ± 21.0 min) and fluoroscopy times (7.7 ± 7.8 minutes, both p <0.01) were shorter compared to the femoral approach. Electrical parameters were similar between the two approaches. There were only two complications during jugular veinous implantations (1 pericardial effusion and 1 dislocation), compared to 16 complications using the femoral approach (1 pericardial effusion, 2 femoral artery injuries and 13 major groin hematomas). The jugular approach may represent a safe and efficient alternative to the femoral implantation method for implantation of the Micra leadless pacemaker.

30 March 2026 in EP Europace
Verified
Journal Article
Open access
KNKent Nilsson
Kent Nilsson
UBUlrika Birgersdotter-Green
Ulrika Birgersdotter-Green
SSShmaila Saleem-Talib
Shmaila Saleem-Talib
DBDeepti Bettampadi
Deepti Bettampadi
ZYZeyuan Yang
Zeyuan Yang
CGChristophe Garweg
Christophe Garweg
Background and Aims: Leadless pacing was developed to avoid complications inherent to transvenous (TV) pacemakers. Among patients with sinus node dysfunction (SND) without atrioventricular block (AVB), TV systems remain standard therapy. Real-world data have shown favourable safety profiles for leadless vs. TV pacemakers. This study aimed to compare 30-day complications and 1-year outcomes—including complications, device-reinterventions, and all-cause mortality—between AVEIR AR leadless pacemakers (LP) and dual-chamber (DCTV) or right-atrial (RATV) TV pacemakers. Methods: Medicare fee-for-service claims were analysed to identify patients undergoing de novo AVEIR AR LP or TV pacemaker implantation from January 2024 to March 2025, with ≥1 year of prior and ≥30 days of post-implant continuous enrolment. The DCTV cohort included patients with SND without permanent atrial fibrillation or AVB; the RATV and LP cohorts included all respective recipients. Outcomes included 30-day and 1-year complications, device-reinterventions, and mortality. Comparisons were adjusted using propensity score derived overlap weights. Results: A total of 428 AVEIR AR, 39 881 DCTV, and 389 RATV patients were included. Thirty-day complications were lower with AVEIR AR compared with DCTV (adjusted 6.7% vs. 9.4%; OR = 0.7) and similar to RATV (6.9% vs. 6.7%). At 1 year, overall complications remained lower in AVEIR AR than DCTV (3.6% vs. 8.5%; HR = 0.4) and RATV (3.3% vs. 7.5%; HR = 0.4) cohorts. Device-related complications were reduced vs. DCTV, and reinterventions were reduced vs. both DCTV and RATV. Mortality was comparable across all groups. Conclusion: AVEIR AR was associated with fewer long-term complications and reinterventions compared with DCTV and RATV, while 1-year mortality remained similar.

4 July 2026 in EP Europace
Verified
Journal Article
Open access
SJStjepan Jurisic
Stjepan Jurisic
JLJeanne du Fay de Lavallaz
Jeanne du Fay de Lavallaz
AGAlessio Gasperetti
Alessio Gasperetti
MEMikhael F El-Chami
Mikhael F El-Chami
SMSchiavone Marco
Schiavone Marco
ABAlexander Breitenstein
Alexander Breitenstein
Aims: As implantation rates of leadless pacemakers (LPM) increase, a growing number of patients will require assessment of LPM removability. This multicentre study investigated the safety and feasibility of removal of tine-based LPMs. Methods and results: We retrospectively analysed consecutive patients who underwent tine-based LPM removal between March 2016 and January 2024 across 11 centres in Europe and the USA. Demographic characteristics, indication for LPM removal, procedural success, and complication rates were assessed. A total of 85 patients [median age 73 years (IQR 64–82)] were included. Indications for LPM removal included temporary use after transvenous lead extraction (23.5%), upgrade to a biventricular pacing system (22.4%) or a transvenous dual-chamber pacemaker (9.4%), and increased pacing thresholds (21.2%). The median device dwell time was 96 days (IQR 29–320 days), and the overall procedural success rate was 96.5%. In the majority of cases, removal was performed using a steerable sheath in combination with a single-loop snare. Procedure-related adverse events occurred in 5.9% of patients, including two pericardial effusions and three cases of device embolization. Significant predictors of removal failure (n = 3, 3.5%) were apical device position [odds ratio (OR) 61.8.0; 95% confidence interval (CI) 2.5–788716.3, P = 0.008] and longer device dwell time [OR 1.4; 95% CI 1.1–2.4, P = 0.008]. Conclusion: Removal of tine-based LPMs, typically after short- to mid-term device dwell times, was generally feasible and safe.

18 February 2024 in Reviews in Cardiovascular Medicine
Verified
Journal Article
Open access
PDF file
SSShmaila Saleem-Talib
Shmaila Saleem-Talib
MDMirjam D. Duineveld
Mirjam D. Duineveld
JSJurjan C. Schipper
Jurjan C. Schipper
AHArnaud D. Hauer
Arnaud D. Hauer
HRHemanth Ramanna
Hemanth Ramanna
MSMichael G. Scheffer
Michael G. Scheffer
Background: Cardiac resynchronization therapy (CRT) is a well-established therapy for patients with heart failure (HF). However, 30% of HF patients do not show any improvement in clinical status after CRT implantation. In this study, we report our echocardiography-based CRT optimization methodology, in daily practice at our CRT referral center. Methods: We included 350 ambulatory patients, who were referred to our center for optimization after CRT implantation. A protocol-driven echocardiographic approach for adjusting mechanical dyssynchrony, whereby adjusting for ventriculoventricular (VV) delays with strain and atrioventricular (AV) delays with Doppler echocardiography was performed. We defined changes in left ventricular ejection fraction (LVEF) and New York Heart Association (NYHA) classes as outcome variables in the evaluation of the CRT outcomes. Results: Optimization was obtained in 288 (82%) patients. VV and AV timings were adjusted to 61% and 51%, respectively. In 3%, biventricular pacing was turned off and in 3% left ventricular (LV) only pacing was programmed. The LVEF and NYHA class showed significant improvements in all patients who underwent CRT optimization. Conclusions: CRT optimization remains valuable in improving LVEF and functional status measured using the NYHA class in all patients receiving CRT devices.